CINECA IRIS Institutional Research Information System

RUDA', Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.248
EU - Europa 3.239
AS - Asia 1.472
SA - Sud America 77
AF - Africa 37
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 11
Totale 10.109
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.161
IT - Italia 910
CN - Cina 876
IE - Irlanda 547
SE - Svezia 319
FR - Francia 270
UA - Ucraina 252
DE - Germania 228
FI - Finlandia 184
KR - Corea 146
GB - Regno Unito 131
VN - Vietnam 123
JP - Giappone 108
PL - Polonia 95
IN - India 61
CA - Canada 60
ES - Italia 56
BR - Brasile 51
NL - Olanda 51
BE - Belgio 40
TR - Turchia 36
SG - Singapore 29
CH - Svizzera 25
AU - Australia 24
MX - Messico 24
AT - Austria 23
TW - Taiwan 22
RU - Federazione Russa 19
HK - Hong Kong 18
PT - Portogallo 18
SN - Senegal 18
DK - Danimarca 10
EU - Europa 10
GR - Grecia 10
MY - Malesia 10
NO - Norvegia 10
NG - Nigeria 9
AR - Argentina 8
ID - Indonesia 8
RO - Romania 8
RS - Serbia 8
UZ - Uzbekistan 7
IL - Israele 6
BG - Bulgaria 5
CL - Cile 5
CO - Colombia 5
PE - Perù 5
HR - Croazia 4
SA - Arabia Saudita 4
TH - Thailandia 4
LT - Lituania 3
MA - Marocco 3
PK - Pakistan 3
SI - Slovenia 3
AM - Armenia 2
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
HU - Ungheria 2
IQ - Iraq 2
IR - Iran 2
LU - Lussemburgo 2
PA - Panama 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CR - Costa Rica 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
ET - Etiopia 1
FK - Isole Falkland (Malvinas) 1
GH - Ghana 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
Totale 10.109
Salva come PNG Salva come JPEG
Città #
Chandler 708
Dublin 545
Beijing 476
Fairfield 381
Houston 300
Torino 245
Ashburn 238
Woodbridge 226
Wilmington 200
Medford 193
Ann Arbor 171
Nyköping 171
Princeton 166
Villeurbanne 165
Seattle 152
Cambridge 132
Jacksonville 127
Pisa 106
Dearborn 96
Redwood City 94
Warsaw 88
Dong Ket 79
Milan 55
Hangzhou 47
Turin 47
New York 44
Boston 40
Fremont 39
Shanghai 35
Boardman 31
Norwalk 28
Toronto 28
Chengdu 25
Nanjing 25
Rome 25
San Diego 24
Tokyo 24
Seoul 23
Kunming 20
Guangzhou 19
London 19
Berlin 18
Brussels 18
Wuhan 16
Singapore 15
Vienna 15
Buffalo 14
Florence 14
Istanbul 14
Jinan 14
Munich 14
Taipei 14
Washington 14
Verona 13
Chongqing 12
Hefei 12
Helsinki 12
Paris 12
Phoenix 12
Zhengzhou 12
Genova 10
Lappeenranta 10
Mountain View 10
Silver Spring 9
Abuja 8
Duncan 8
Fuzhou 8
Guiyang 8
Madrid 8
Bari 7
Catania 7
Changsha 7
Falls Church 7
Groningen 7
Hamamatsu 7
Kent 7
Los Angeles 7
Redmond 7
Shenyang 7
Zurich 7
Barcelona 6
Central District 6
Danbury 6
Hanoi 6
Hebei 6
Izmir 6
Orio Canavese 6
Osaka 6
Padova 6
Pune 6
San Francisco 6
St Petersburg 6
São Paulo 6
Upper Marlboro 6
Amsterdam 5
Chicago 5
Lachine 5
Lanzhou 5
Lyon 5
Madison 5
Totale 6.192
Salva come PNG Salva come JPEG
Nome #
Epilepsy and brain tumors. 526
Targeted therapy in brain metastasis 391
MGMT promoter methylation in plasma of glioma patients receiving temozolomide. 326
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016 262
Response to combined radiotherapy and chemotherapy of a leptomeningeal spread from choroid plexus carcinoma: case report. 246
Five-year survival after first-ever ischaemic stroke is worse in total anterior circulation infarcts: the SINPAC cohort. 211
Anti-Angiogenic Approaches to Malignant Gliomas 202
Gliomatosis cerebri: A review 193
Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide 168
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas 166
Mechanisms and therapy for cancer metastasis to the brain 158
Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas 151
Skin metastases of glioblastoma in the absence of intracranial progression are associated with a shift towards a mesenchymal immunophenotype: report of two cases 147
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma 146
Meningeal carcinomatosis underdiagnosis and overestimation: Incidence in a large consecutive and unselected population of breast cancer patients 144
Does valproic acid affect tumor growth and improve survival in glioblastomas? 143
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 139
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial 125
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target 112
Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. 111
Neoplasie del sistema nervoso centrale 101
Stroke and transient ischaemic attack in 18 neurology departments from two Italian Regions: the SINPAC database 99
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology) 96
Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor 96
Efficacy of radiation therapy for epileptic seizures of grade 2 and 3 gliomas: a retrospective study 95
Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis? 95
Liquid biopsy in Central Nervous System metastases: a RANO review and proposals for clinical applications 94
Gliomi: monitoraggio dello stato di metilazione del gene MGMT nel DNA plasmatico dei pazienti sottoposti a chemioterapia con agenti alchilanti 88
Better see to better agree: Phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds 87
EANO guidelines for the diagnosis and treatment of ependymal tumors. 87
Prognostic characterization of higher-grade meningiomas: A histopathological score to predict progression and outcome 85
Molecularly based management of gliomas in clinical practice 83
Controversies in management of low-grade gliomas in light of new data from clinical trials. 82
Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring 82
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study 77
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. 75
Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO) 75
Extent of surgery in low-grade gliomas: an old question in a new context. 73
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours 73
Antiangiogenic therapy of brain tumors: The role of bevacizumab 72
Current clinical management of elderly patients with glioma 71
Neoplastic meningitis: Clinico-diagnostic aspects [Meningite neoplastica: Aspetti clinico-diagnostici] 69
Pathological prognostic markers in central nervous system solitary fibrous tumour/ hemangiopericytoma: Evidence from a small series 69
Adverse effects of antiepileptic drugs in brain tumors: Preliminary data of a multi-institutional survey. Are new antiepileptic drugs less toxic? 67
TRATTAMENTO DELLE METASTASI CEREBRALI 66
Impiego di temozolomide negli ependimomi intracranici recidivanti dell’adulto 65
Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments 65
Correction to: Efficacy of initial temozolomide for high‑risk low grade gliomas in a phase II AINO (Italian Association for Neuro‑Oncology) study: a post‑hoc analysis within molecular subgroups of WHO 2016 61
Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. 60
Supratotal Resection of Glioblastoma: Is Less More? 60
Neuro-Oncologic Emergencies 59
Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas 59
Meningiomas after cranial radiotherapy for childhood cancer: a single institution experience. 59
Expression analysis and prognostic/predictive significance of a panel of microRNAs (miR-124a, miR-381, miR-637) in primary IDH-wildtype glioblastoma 59
Diffusion-Weighted Magnetic Resonance Imaging and ADC Maps in the Diagnosis of Intracranial Cystic or Necrotic Lesions. A retrospective Study on 49 Patients 58
Is there a Role for Bevacizumab in Non-Glial Tumors? 56
NCOG-19. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE INSTITUTIONAL SERIES OF 160 PATIENTS 56
Role of diffusion- and perfusion-weighted MR imaging for brain tumour characterisation. 55
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). 55
Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy 55
Imaging and clinical end points in brain metastases trials. 55
A phase II study of first-line temozolomide and second-line PCV in recurrent/progressive malignant gliomas. 54
What is New in the Management of Epilepsy in Gliomas? 54
Leptomeningeal metastases: a RANO proposal for response criteria. 54
Choosing appropriate chemotherapy for diffusely infiltrating WHO grade II gliomas in adults. 52
Ependymoma: Evaluation and Management Updates 52
[Efficacy of liposomal cytarabine in neoplastic meningitis] 51
Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. 51
Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response 49
Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps 49
Second-line PCV in recurrent or progressive glioblastomas: A phase II study 48
PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. 48
Epilepsy in brain metastasis: an emerging entity 48
Management of brain metastases. 48
Efficacy of topiramate in patients with gliomas 47
Temozolomide in rare brain tumors of the adult: a prospective study. 47
Salvage therapy with bevacizumab and fotemustine in recurrent high grade gliomas 47
Treatment of brain metastasis: current status and future directions 47
Brain metastases: current management and new developments 46
Chemotherapy 46
Brain metastasis as complication of systemic cancers 46
Brain metastases from unknown primary tumour: a prospective study. 46
Depatuxizumab mafodotin (Depatux-m) plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of italian association of neuro-oncology (aino) 46
Leptomeningeal metastases from non-small cell lung cancer: state of the art and recent advances 44
IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups 44
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology 43
Neurologic complications of chemotherapy and other newer and experimental approaches 43
Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling 43
Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series 43
Different timing to use bevacizumab in patients with recurrent glioblastoma: Early versus delayed administration 42
Pharmacologic therapies for malignant glioma: a guide for clinicians. 41
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors 41
Second-line PCV in recurrent or progressive glioblastomas: A phase II study 40
Natural history and management of brainstem gliomas in adults. A retrospective Italian study 39
Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials 39
Brain metastasis from unknown primary tumour: Moving from old retrospective studies to clinical trials on targeted agents 39
Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects 39
Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma 39
Neuro-oncology: new insights and advances in treatment 38
Blood–Brain Barrier in Brain Tumors: Biology and Clinical Relevance 38
Totale 8.832
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.342
article - articoli 0
book - libri 0
conference - conferenze 2.211
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.553
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019354 0 0 0 0 0 0 0 0 0 0 250 104
2019/20201.599 86 58 78 192 89 217 192 153 160 153 116 105
2020/20211.313 104 102 137 87 112 97 102 81 105 122 77 187
2021/20221.670 82 50 92 116 72 118 79 87 44 174 404 352
2022/20232.516 227 186 73 230 227 603 306 161 244 63 135 61
2023/2024876 159 193 75 74 59 103 43 62 8 97 3 0
Totale 10.621